Acrivon appoints Adam Levy as CFO; Rasmus Holm-Jorgensen steps down effective April 1, 2025

Acrivon Therapeutics, Inc.

Rasmus Holm-Jorgensen resigns as CFO effective April 1, 2025, for personal reasons to pursue Europe-based opportunity; no disagreement.
Adam Levy, current SVP Corporate Affairs & Investor Relations, appointed CFO effective April 1, 2025.
Levy's annual base salary set at $490,000, bonus target 40%, plus 35,209 stock options vesting over 4 years.
Levy has over 25 years biopharma finance/IR experience, previously at Gilead, Turning Point Therapeutics, Zentalis.
Levy required to relocate to Boston area within 9 months; up to $50,000 relocation reimbursement with 24-month clawback.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Rasmus Holm-Jorgensen

Chief Financial Officer

ACRV · Acrivon Therapeutics, Inc.

Effective: 2025-04-01
Successor: Adam Levy
Filed: March 14, 2025, 7:59 PM ET

On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.

Appointed

Adam Levy

Chief Financial Officer

ACRV · Acrivon Therapeutics, Inc.

Effective: 2025-04-01
Filed: March 14, 2025, 7:59 PM ET

On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rasmus Holm-Jorgensen resigned as Chief Financial Officer at Acrivon Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Adam Levy was appointed as Chief Financial Officer at Acrivon Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).

View on SEC.gov

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-039520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.